Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Indianapolis, Indiana

This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
8612
Shown on this page
12
Current sort
Recently updated
Location scope
Indianapolis, IN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Indianapolis, Indiana. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 541–552 of 8,612 matching trials in Indianapolis, IN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Not applicable Interventional

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

NCT05124808
View directory record Official record
Conditions
Gestational Diabetes, Pregnancy, High Risk, Overweight and Obesity
Interventions
Intensive glycemic targets, Standard glycemic targets
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Norman, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

NCT05857930
View directory record Official record
Conditions
Recurrent Wheezing, Wheezing Lower Respiratory Illness
Interventions
OM-85, Placebo
Drug
Lead sponsor
OM Pharma SA
Industry
Eligibility
6 Months to 72 Months
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Completed Phase 2 Interventional Results available

Ruxolitinib for Premalignant Breast Disease

NCT02928978
View directory record Official record
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

ABVN Phase 1 - Ear Stimulation

NCT04206540
View directory record Official record
Conditions
Healthy Subjects
Interventions
Transcutaneous Auricular Vagus Nerve Stimulation
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Active, not recruiting Phase 3 Interventional

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
12
States / cities
Oakland, California • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Ripretinib, Sunitinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
43
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Kinesio Tape on Delayed Onset Muscle Soreness

NCT04128670
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
Kinesiotape
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil, Placebo, Prednisone, Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
24
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878
View directory record Official record
Conditions
Moderately to Severely Active Crohns Disease
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
95
States / cities
Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Recruiting Not applicable Interventional

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

NCT06423430
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Sham-stimulation, Active-stimulation
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
22 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST
Completed Phase 3 Interventional

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04225871
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
zilucoplan (RA101495)
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
33
States / cities
Mobile, Alabama • Phoenix, Arizona • Irvine, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 11:45 AM EST